These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 23765538

  • 1. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E, Elstein D, Peleg A, Reinus C, Zimran A, Amir G.
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [Abstract] [Full Text] [Related]

  • 2. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 3. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM.
    Bull Acad Natl Med; 2002 Apr 20; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [Abstract] [Full Text] [Related]

  • 4. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar 20; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

  • 5. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
    El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK.
    J Inherit Metab Dis; 2006 Feb 20; 29(1):92-8. PubMed ID: 16601874
    [Abstract] [Full Text] [Related]

  • 6. [Characterization of the genotypes of patients with Gaucher disease type 1 in the Russian Federation].
    Lukina KA, Fevraleva IS, Sysoeva EP, Mamonov BE, Sudarikov AB, Lukina EA.
    Ter Arkh; 2013 Feb 20; 85(7):72-5. PubMed ID: 24137950
    [Abstract] [Full Text] [Related]

  • 7. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B.
    Mol Genet Metab; 2014 Nov 20; 113(3):213-8. PubMed ID: 25127542
    [Abstract] [Full Text] [Related]

  • 8. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):119-23. PubMed ID: 20727796
    [Abstract] [Full Text] [Related]

  • 9. Cessation of enzyme replacement therapy in Gaucher disease.
    Grinzaid KA, Geller E, Hanna SL, Elsas LJ.
    Genet Med; 2002 Jan 15; 4(6):427-33. PubMed ID: 12509713
    [Abstract] [Full Text] [Related]

  • 10. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight.
    Ucar SK, Coker M, Argin M, Akman S, Kara S, Simsek DG, Darcan S.
    Mol Genet Metab; 2009 Jan 15; 96(1):50-1. PubMed ID: 19006678
    [Abstract] [Full Text] [Related]

  • 11. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
    Grigorescu-Sido P, Drugan C, Alkhzouz C, Zimmermann A, Coldea C, Denes C, Grigorescu MD, Cret V, Bucerzan S.
    Eur J Intern Med; 2010 Apr 15; 21(2):104-13. PubMed ID: 20206881
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 13. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
    Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A.
    Blood Cells Mol Dis; 2014 Jan 15; 53(1-2):56-60. PubMed ID: 24581483
    [Abstract] [Full Text] [Related]

  • 14. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK, Batista JL, Andersson HC, Balwani M, Burrow TA, Charrow J, Kaplan P, Khan A, Kishnani PS, Kolodny EH, Rosenbloom B, Scott CR, Weinreb N.
    Am J Hematol; 2017 Sep 15; 92(9):929-939. PubMed ID: 28569047
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study.
    Rudzki Z, Okoń K, Machaczka M, Rucińska M, Papla B, Skotnicki AB.
    Eur J Haematol; 2003 May 15; 70(5):273-81. PubMed ID: 12694162
    [Abstract] [Full Text] [Related]

  • 16. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ.
    Isr Med Assoc J; 2000 Feb 15; 2(2):158-63. PubMed ID: 10804944
    [Abstract] [Full Text] [Related]

  • 17. RecTL: a complex allele of the glucocerebrosidase gene associated with a mild clinical course of Gaucher disease.
    Zimran A, Horowitz M.
    Am J Med Genet; 1994 Mar 01; 50(1):74-8. PubMed ID: 8160756
    [Abstract] [Full Text] [Related]

  • 18. [Gaucher disease: MR evaluation of bone marrow features during treatment with enzyme replacement].
    Poll LW, vom Dahl S, Koch JA, Börner D, Willers R, Cohnen M, Jung G, Scherer A, Niederau C, Häussinger D, Mödder U.
    Rofo; 2001 Oct 01; 173(10):931-7. PubMed ID: 11588682
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
    Laudemann K, Moos L, Mengel E, Lollert A, Hoffmann C, Brixius-Huth M, Wagner D, Düber C, Staatz G.
    Blood Cells Mol Dis; 2016 Mar 01; 57():35-41. PubMed ID: 26852653
    [Abstract] [Full Text] [Related]

  • 20. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 01; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.